Endpoints
The primary endpoint of this study was to evaluate the incidence of CTLS
in patients with high-grade B-cell lymphoma treated with a fractionated
rituximab schedule. Secondary end-points were to report the incidence of
LTLS and other adverse events of interest (e.g. infusion reactions),
explore clinical risk factors related with CTLS and report
progression-free survival (PFS) and overall survival (OS) of the whole
cohort, by TLS / no TLS and IPI subgroups.